Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term “novel transcript, antisense to RGPD6” refers to a putative or predicted RNA molecule transcribed from the DNA strand opposite to the RGPD6 (RANBP2 Like And GRIP Domain Containing 6) gene locus. Antisense transcripts are typically long noncoding RNAs (lncRNAs) that may regulate the expression of the sense gene (in this case, RGPD6) by various mechanisms, such as transcriptional interference or epigenetic modification. However, there is no evidence that this transcript encodes a protein, nor is it a recognized therapeutic target, receptor, enzyme, or transporter. The Ensembl gene identifier ENSG00000304376 does not map to any confirmed gene or transcript in major databases as of this writing[3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RGPD6.